Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MorphoSys 4 ADR Representing Ord Shs MOR

Alternate Symbol(s):  MPSYF | MPHSF

Healthcare Technology Biotechnology Scientific & Technical Instruments
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma... see more

Recent & Breaking News (NDAQ:MOR)

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Business Wire December 11, 2021

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Accesswire December 11, 2021

Corporate Calendar 2022

Accesswire November 29, 2021

MorphoSys AG Reports First Nine Months and Third Quarter 2021 Results

Accesswire November 11, 2021

MorphoSys Announces Departure of Roland Wandeler

Accesswire November 9, 2021

MorphoSys Presents Interim Results from M-PLACE Study with Felzartamab during American Society of Nephrology Annual Meeting

Accesswire November 4, 2021

MorphoSys to Present MANIFEST and RE-MIND2 Data from Expanded Hematology-Oncology Portfolio at the 2021 American Society of Hematology (ASH) Annual Meeting

Accesswire November 4, 2021

MorphoSys AG Announces Monjuvi(R) Sales for the First Nine Months and Third Quarter of 2021 and Invitation to the Upcoming Conference Call on November 11, 2021

Accesswire November 2, 2021

MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy

Accesswire October 20, 2021

MorphoSys' Licensing Partner Roche Received Breakthrough Therapy Designation for Gantenerumab in Alzheimer's Disease

Accesswire October 11, 2021

MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Accesswire August 26, 2021

Incyte and MorphoSys Announce the European Commission Approval of Minjuvi® (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Business Wire August 26, 2021

MorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China

Accesswire August 17, 2021